Hanata, Norio
Ota, Mineto
Tsuchida, Yumi
Nagafuchi, Yasuo
Okamura, Tomohisa
Shoda, Hirofumi
Fujio, Keishi
Funding for this research was provided by:
Japan Society for the Promotion of Science (20K17439)
Chugai Pharmaceutical
Article History
Received: 15 June 2022
Accepted: 25 October 2022
First Online: 1 November 2022
Competing interests
: N.H. has received grants from GlaxoSmithKline. M.O. belongs to the Social Cooperation Program, Department of functional genomics and immunological diseases, supported by Chugai Pharmaceutical, and has received speaking fees from BMS, MSD, and Chugai. Y.T. has received grants from GlaxoSmithKline and speaking fees from GlaxoSmithKline and Chugai. Y.N. belongs to the Social Cooperation Program, Department of functional genomics and immunological diseases, supported by Chugai Pharmaceutical, and has received financial support or fees from BMS, Chugai, GlaxoSmithKline, Kissei, Mitsubishi Tanabe, and Pfizer. T.O. belongs to the Social Cooperation Program, Department of functional genomics and immunological diseases, supported by Chugai Pharmaceutical. H.S. has received speaking fees and grants from Takeda, BMS, Asahi Kasei, Sanofi, Eli Lilly, Janssen, Astellas, Pfizer, Chugai, UCB, Abbvie, Eisai, Boehringer Ingelheim, Gilead, Novartis, and Daiichi-Sankyo. K.F. has received speaking fees, and/or honoraria from Tanabe Mitsubishi, Bristol Myers, Eli Lilly, Chugai, Jansen, Pfizer, Ono, AbbVie, Ayumi, Astellas, Sanofi, Novartis, Daiichi Sankyo, Eisai, Asahi Kasei, Japan Blood Products Organization, and Kowa, and has received research grants from Tanabe Mitsubishi, Bristol Myers, Eli Lilly, Chugai, AbbVie, Ayumi, Astellas, Sanofi, Eisai, Tsumura and Co., and Asahi Kasei.